CLPP and cancer: ONC206, a second-generation imipridone, has been shown to exhibit potent anti-cancer activity through multiple mechanisms, including the antagonism of dopamine receptor D2 (DRD2), CLpP agonism, and TRAIL activation, disrupting mitochondrial protein homeostasis and inducing cellular stress responses [19,24].